The Immune Tolerance Network (ITN), led by Benaroya Research Institute (BRI), has made major breakthroughs in fighting peanut allergies.
Carla Greenbaum, MD, has been named chair of Type 1 Diabetes TrialNet.
Over the last few years, several unique and pioneering technologies at BRI have been combined to create a “pipeline” approach to find and study rare disease-associated cells.
A simple blood test for family members of those living with type 1 diabetes may detect autoantibodies that show an increased risk years before symptoms appear.
The Immune Tolerance Network’s (ITN) TrialShare Clinical Trials Research Portal has won the National Academy of Scie
© 2020 Benaroya Research Institute at Virginia Mason. 1201 Ninth Avenue, Seattle, WA 98101-2795
Your donation to the COVID-19 Rapid Response Fund will directly support urgent research into the immune system response to the virus. With your help, we can get to answers faster to bring an end to this public health crisis.
No thanks, close this window